Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel class of anti-IL-12p40 antibodies: potent neutralization via inhibition of IL-12-IL-12Rβ2 and IL-23-IL-23R.

mAbs - 1 Jan 2000

Clarke Adam W, Poulton Lynn, Wai Hoi Yi, Walker Stuart A, Victor Shanti David, Domagala Teresa, Mraovic Dragana, Butt Danyal, Shewmaker Nina, Jennings Philip, Doyle Anthony G

Abstract excerpt

While current therapeutic antibodies bind to IL-12 and IL-23 and inhibit their binding to IL-12Rβ1, we describe a novel antibody, termed 6F6, that binds to IL-12 and IL-23 and inhibits the interaction of IL-12 and IL-23 with their cognate signalling receptors IL-12Rβ2 and IL23R. This antibody doe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Hybridomas
Share to Interleukin-12

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-12 Subunit p40

Share to Interleukin-23

Share to Jurkat Cells

Share to Receptors, Interleukin

Share to Receptors, Interleukin-12

Source

Open in PubMed Open full text

Identifiers

PMID: 20724822
DOI: 10.4161/mabs.2.5.13081
PMCID: PMC2958575

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20724822-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel class of anti-IL-12p40 antibodies: potent neutralization via inhibition of IL-12-IL-12Rβ2 and IL-23-IL-23R.PMID 20724822Read ↗

IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.Semantic proximity Read ↗

IL-12 and IL-23—Close Relatives with Structural Homologies but Distinct Immunological FunctionsSemantic proximity Read ↗

Signaling by IL‐12 and IL‐23 and the immunoregulatory roles of STAT4Semantic proximity Read ↗

The Dichotomous Pattern of IL-12R and IL-23R Expression Elucidates the Role of IL-12 and IL-23 in InflammationSemantic proximity Read ↗

Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23Semantic proximity Read ↗

A novel human truncated IL12rβ1-Fc fusion protein ameliorates experimental autoimmune encephalomyelitis via specific binding of p40 to inhibit Th1 and Th17 cell differentiation.Semantic proximity Read ↗

Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice.Semantic proximity Read ↗

IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseasesSemantic proximity Read ↗

Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signalingSemantic proximity Read ↗

Human IFN-γ immunity to mycobacteria is governed by both IL-12 and IL-23Semantic proximity Read ↗

Human IL-23 is essential for IFN-γ-dependent immunity to mycobacteria.Semantic proximity Read ↗

Characterisation of IL-23 receptor antagonists and disease relevant mutants using fluorescent probes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.